About Day Zero Diagnostics
Day Zero Diagnostics is a Healthcare company based in Boston (United States) founded in 2016. Genome sequencing diagnostics for infectious diseases are developed. Day Zero Diagnostics has raised $48.6 million across 10 funding rounds from investors including NIH, BD and CARB-X. The company has 48 employees. Day Zero Diagnostics offers products and services including epiXact® Service, Whole Genome Sequencing Diagnostics, and Computational Diagnostic Algorithms. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is DAY ZERO DIAGNOSTICS, INC. Its competitors include Cepheid, Karius and OpGen; 3 of its 3 listed competitors have raised funding.
Company details
Day Zero Diagnostics was founded in 2016 in Boston, United States, within the health technology sector. Diagnostic solutions based on machine learning and genomics are provided for infectious diseases. Whole-genome sequencing is utilized in assays such as Blood2Bac and BacDetect to identify infecting bacterial species and drug resistance. Operations focus on advancing rapid diagnostics for clinical applications.
- Headquarters Boston, United States
- Employees 48
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website dayzerodiagnostics.com
- Social LinkedIn X Facebook
- Legal Name Day Zero Diagnostics, Inc
- Total Equity Funding$48.6M (USD)
in 10 rounds
- Latest Funding Round$16M (USD), Series B
Sep 2023
- InvestorsNIH
& 10 more
- Employee Count48
Products & Services of Day Zero Diagnostics
Day Zero Diagnostics offers a comprehensive portfolio of products and services, including epiXact® Service, Whole Genome Sequencing Diagnostics, and Computational Diagnostic Algorithms.
Provides rapid genome sequencing for pathogen relatedness in hospitals.
Offers quick ID and AMR profiling for infectious diseases treatment.
Delivers algorithms for analyzing genomic data in disease diagnostics.
Funding Insights of Day Zero Diagnostics
Day Zero Diagnostics has successfully raised a total of $48.6M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $16 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $48.6M
- Total Rounds 10
- Last Round Series B — $16M
- First Round $3M
(May 2017)
- Investors Count 11
All 10 funding rounds of Day Zero Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $16M | Series B | – | – | – |
| Aug 2023 | $299,989 | Grant | – | – | |
| Oct 2022 | $8.2M | Grant | – | – | |
| Feb 2022 | $21M | Series B | – | Sands Capital | |
| Dec 2020 | $300,000 | Grant | – | – | |
| May 2020 | $6.2M | Grant | – | – | |
| Jul 2019 | Grant | – | – | ||
| Jan 2019 | $8.6M | Series A | – | Triventures | |
| Jun 2018 | Seed | – | HealthTech Arkansas | – | |
| May 2017 | $3M | Seed | – | Golden Seeds, Sands Capital Ventures | – |
11 investors in total: 11 institutional.
Investors in Day Zero Diagnostics
Day Zero Diagnostics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, BD and CARB-X.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A life sciences venture fund is operated with global reach. | panaceaventure.com | |||
Tech & Life-Sciences focused VC Firm investing in the US | goldenseeds.com | New York, United States | ||
Venture capital firm investing in early stage healthcare startups | triventures.vc | Herzliya, Israel | ||
Growth stage tech & life sciences focused VC Firm investing in Asia and the US | sandscapitalventures.com | Arlington, United States | ||
HealthTech Arkansas is focused on driving healthcare innovation in Arkansas. | healthtecharkansas.com | United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States | |
Active, long-term growth equity investments are provided globally. | sandscapital.com | Arlington, United States | ||
BD is recognized for providing innovative medical technology solutions. | 1897 | bd.com | Franklin Lakes, United States | |
| niaid.nih.gov |
Investor details for Day Zero Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Day Zero Diagnostics
17 people are tracked at Day Zero Diagnostics (4 in leadership, 12 in board & advisors, 1 in team); the tracked headcount is 48.
| Name | Role | Group |
|---|---|---|
Jong Lee | CEO & Cofounder | Leadership |
Rene Robert | VP, Product Realization | Leadership |
Dougal Maclaurin | Scientific Co-founder | Leadership |
Melodie Domurad | VP, Medical Affairs | Leadership |
Keith Robison | Scientific Advisor | Board & advisors |
Sally Hojvat | Regulatory Advisor | Board & advisors |
Amy Mathers | Clinical Advisor | Board & advisors |
David Hooper | Clinical Advisor | Board & advisors |
Robert J. Crisp | Scientific Advisor | Board & advisors |
Jared Simpson | Scientific Advisor | Board & advisors |
Yonatan Grad | Scientific Advisor | Board & advisors |
Stephen Calderwood | Clinical Advisor | Board & advisors |
Robin Patel | Clinical and Scientific Advisor | Board & advisors |
Gail Marcus | Director | Board & advisors |
Stephen Zachary | Director | Board & advisors |
Peter Fitzgerald | Director | Board & advisors |
Linnea Sahlberg | Senior Technical Product Manager | Team |
Complete people profiles for Day Zero Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Day Zero Diagnostics
3 dated milestones of Day Zero Diagnostics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Day Zero Diagnostics is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Series B, of $16.0M.
Competitors of Day Zero Diagnostics
Day Zero Diagnostics has 3 listed competitors in our database, 3 of them funded. They include Cepheid, Karius and OpGen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cepheid.com | 1996 | Sunnyvale, United States | $19.1M | 1,299 | Developer of molecular diagnostic testing solutions | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| opgen.com | 2002 | Rockville, United States | $77.51M | 100 | Developer of diagnostics and bioinformatics platforms for providers |
Detailed competitors of Day Zero Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Day Zero Diagnostics
The website of Day Zero Diagnostics (dayzerodiagnostics.com) receives about 1.4K visits a month and ranks #5,790,285 among all websites worldwide, #6,253 in Biotechnology and Pharmaceuticals.
- Monthly visits1.4K
▼ 46.8% vs previous month
- Unique visitors1.2K
per month
- Global rank#5,790,285
among all websites
- Category rank#6,253
Health · Biotechnology and Pharmaceuticals
- Bounce rate32%
- Pages per visit2.0
- Average visit36 sec
- DevicesDesktop 24% · Mobile 76%
Websites whose visitors overlap most with Day Zero Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sherlock.bio | 100% | 2.8K | #4,929,420 | View details | |
| dynotx.com | 95% | 14.4K | #2,089,404 | View details | |
agingresearch.org | agingresearch.org | 64% | #1,093,690 | – | |
| atriushealth.org | 43% | 1.3M | #31,755 | View details | |
liliumdiagnostics.com | liliumdiagnostics.com | 30% | #7,166,163 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Day Zero Diagnostics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Day Zero Diagnostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Day Zero Diagnostics
Complete news archive for Day Zero Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Day Zero Diagnostics
Day Zero Diagnostics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Day Zero Diagnostics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Day Zero Diagnostics is a funded company, having raised a total of $48.6M across 10 funding rounds to date. The company's 1st funding round was a Seed of $3M, raised on May 2017.
Day Zero Diagnostics has 48 employees.
Day Zero Diagnostics was founded in 2016 in Boston, United States, within the health technology sector. Diagnostic solutions based on machine learning and genomics are provided for infectious diseases. Whole-genome sequencing is utilized in assays such as Blood2Bac and BacDetect to identify infecting bacterial species and drug resistance. Operations focus on advancing rapid diagnostics for clinical applications.
Day Zero Diagnostics offers epiXact® Service, Whole Genome Sequencing Diagnostics, and Computational Diagnostic Algorithms.
Day Zero Diagnostics has 11 investors. Key investors include NIH, BD, CARB-X, Sands Capital, and Panacea Venture.
Day Zero Diagnostics operates through Day Zero Diagnostics, Inc.